Injective Surges 6.5% on ETF Rumors, Supply Squeeze

Injective's 6.5% Surge: A Deep Dive into the Catalysts

Injective’s roughly 6.5% 24-hour move appears driven by renewed ETF and institutional narratives around INJ, amplified by deflationary “supply squeeze” tokenomics and social buzz, rather than the broader market.

ETF Narrative and Staked INJ Products

The strongest short-term catalyst is a cluster of headlines and social posts about potential US ETFs tied to INJ, including a staked version.

1. In interviews at Korea Blockchain Week 2026, Injective CEO Eric Chen said he expects US ETFs tied to INJ to launch “before 2027,” adding that “2027 is a little bit too far” and the timing is “way sooner than I expected.” The SEC is reviewing two products: the 21Shares Injective ETF and the Canary Staked INJ ETF, both of which amended their S-1 filings in September 2026.Injective CEO ETF comments

1. Similar coverage from other outlets and venues, including an exchange news post, repeated that Chen expects US INJ ETFs to arrive sooner than 2027 and highlighted Injective Institutional Services’ role as an SEC-registered transfer agent as part of a broader licensing push.Gate article on INJ ETF expectations

1. Within the last 24 hours, social posts on X explicitly hyped a “staked INJ ETF” (ticker “INJC”) and framed it as “institutions are coming in, fresh liquidity is on the way, and holders get yield on the product itself.”Example X post about staked INJ ETF